Search our Database of Scientific Publications and Authors

I’m looking for a

    9690 results match your criteria Acromegaly

    1 OF 194

    Cross-sectional prevalence of pancreatic cystic lesions in patients with acromegaly, a single-center experience.
    Pituitary 2017 May 24. Epub 2017 May 24.
    Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
    Purpose: Acromegaly is a disease associated with an increased risk for several kinds of neoplasms including colon and thyroid cancer. Although the association between acromegaly and pancreatic neoplasms has not been elucidated, it has recently been reported that GNAS gene mutations were found in 58% of intraductal papillary mucinous neoplasms (IPMNs), which are representative pancreatic cystic lesions, suggesting a link between IPMNs and acromegaly. To assess the prevalence of pancreatic cystic lesions in patients with acromegaly, we performed a retrospective cross-sectional single institute study. Read More

    Prescription patterns of long-acting somatostatin analogues.
    SAGE Open Med 2017 9;5:2050312117694795. Epub 2017 Mar 9.
    Grupo de Investigación en Farmacoepidemiología y Farmacovigilancia, Universidad Tecnológica de Pereira-Audifarma S.A., Pereira, Colombia.
    Background: Acromegaly and endocrine tumors are uncommon morbidities that are currently treated with different drugs.

    Objective: To determine the prescription patterns of somatostatin analogues in patients affiliated with the Health System of Colombia.

    Methods: Retrospective cohort study of patients of any age and sex treated with octreotide or lanreotide between January 2011 and August 2015. Read More

    Standardization of Growth Hormone and Insulin-like Growth Factor-I Measurements.
    Pediatr Endocrinol Rev 2017 Mar;14(Suppl 1):209-215
    Department of Molecular Endocrinology, National Research Institute for Child Health and Development 2-10-1 Okura, Setagaya-ku, Tokyo 157-8535, Japan.
    Measurement of the levels of growth hormone (GH) and its related factor insulin-like growth factor I (IGF-I) is essential for the diagnosis and treatment of GH deficiency (GHD) and conditions related to excess GH such as acromegaly and pituitary gigantism. Measurement of GH levels is also used as an indicator of hypothalamic-pituitary function. Because of the marked variability in GH measurements among kits, the Study Committee for GH and Its Related Factors of The Foundation for Growth Science, Japan standardized GH values measured with various commercially available GH assay kits in Japan. Read More

    The Longevity Hormone Klotho is a New Player in the Interacion of the Growth Hormone/Insulin-Like Growth Factor 1 Axis.
    Pediatr Endocrinol Rev 2016 Sep;14(1):9-18
    Pediatric Endocrinology and Diabetes unit, The Edmond and Lily Safra Children's Hospital, Chaim Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Israel, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
    Klotho was first discovered as an aging-suppressor gene. Mice that do not express klotho die prematurely with multiple symptoms of aging, several of which are also characteristic of decreased GH/IGF-1 axis activity. Klotho is highly expressed in the brain, the kidney, and parathyroid and pituitary glands, but can also serve as a circulating hormone by its shedding, forming soluble klotho (sKlotho) that can be detected in blood, cerebrospinal fluid and urine. Read More

    Evaluation of macular and peripapillary choroidal thickness, macular volume and retinal nerve fiber layer in acromegaly patients.
    Int Ophthalmol 2017 May 15. Epub 2017 May 15.
    Department of Ophthalmology, Medical Faculty, Bulent Ecevit University, Zonguldak, Turkey.
    Purpose: To evaluate macular volume, retinal nerve fiber layer, and macular and peripapillary choroidal thickness in acromegaly patients.

    Method: In this prospective, case-control study, 31 patients with acromegaly and 32 healthy subjects were recruited. Only right eyes were evaluated. Read More

    Classification of patients with GH disorders may vary according to the IGF-I assay.
    J Clin Endocrinol Metab 2017 May 12. Epub 2017 May 12.
    Service d'Endocrinologie et des Maladies de la Reproduction and Centre de Référence des Maladies Endocriniennes Rares de la Croissance (M.M., E.K., J.Y., P.C.), Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Hôpital de Bicêtre, Unité de Recherche Clinique (H.A, A.A.), and Service de Génétique Moléculaire, Pharmacogénétique et Hormonologie (S.B-T.), Le Kremlin-Bicêtre, F94275, France; Inserm 1185 (E.K., S.B-T., J.Y., P.C.), Fac Med Paris Sud, Université Paris-Saclay, Le Kremlin-Bicêtre, F-94276, France; and Laboratoire d'Hormonologie (C.M.), Centre Hospitalier Universitaire de Rennes, Centre d'Investigation Clinique Plurithématique, Inserm 1414, Hôpital Pontchaillou, Rennes, F29000, France; Service des Explorations Fonctionnelles (M-L.P., J.-C.S.), Assistance Publique-Hôpitaux de Paris, Hôpital Necker-Enfants Malades, Paris, F75015, France.
    Context: IGF-I measurement is essential for the diagnosis and management of GH disorders. However, patient classification may vary substantially according to the assay technique.

    Objective: We compared individual patient data and classifications obtained with six different IGF-I assay kits in a group of patients with various GH disorders. Read More

    Somatotropinomas inadequately controlled with octreotide may over-respond to pasireotide: the importance of dose adjustment to achieve long-term biochemical control.
    Hormones (Athens) 2017 Jan;16(1):84-91
    Department of Internal Medicine and Endocrine Unit, Medical School and Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
    Objective: To present two female patients with acromegaly inadequately controlled with long-acting octreotide who were subsequently treated with the multireceptor-targeted somatostatin analogue pasireotide that over-suppressed IGF-1 levels.

    Methods: We report two patients who failed surgery and received long-acting octreotide 20-30 mg/month as part of two double-blind, Phase III clinical trials. After 6-12 months of octreotide treatment, both patients remained inadequately controlled and were switched to long-acting pasireotide 40 mg/month as part of a crossover extension phase. Read More

    Treatment of acromegaly patients at the Federal University of Triângulo Mineiro (UFTM): Experience Report.
    Clinics (Sao Paulo) 2017 Apr;72(4):218-223
    Divisão de Endocrinologia e Metabolismo, Universidade Federal do Triângulo Mineiro, Uberaba, MG, BR.
    Objective:: To evaluate the effectiveness of the treatment of acromegaly patients at the Federal University of Triangulo Mineiro.

    Methods:: Cross-sectional and retrospective study of thirty cases treated over a period of two decades.

    Results:: 17 men (56. Read More

    Acromegaly in a non-diabetic cat.
    JFMS Open Rep 2016 Jan-Jun;2(1):2055116916646585. Epub 2016 Apr 25.
    Department of Clinical Sciences of Companion Animals, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.
    Case Summary: A 14-year-old, neutered male European shorthair cat was evaluated for a routine health check. The owner did not report any clinical signs except for respiratory stridor. On physical examination the main findings were broad facial features and increased interdental spaces. Read More

    GH-secreting pituitary macroadenoma (acromegaly) associated with progressive dental malocclusion and refractory CPAP treatment.
    Head Face Med 2017 May 10;13(1). Epub 2017 May 10.
    Chief of Oral and Maxillofacial Department, Hospital Universitari Mútua de Terrassa, Universitat de Barcelona, Terrassa, Spain.
    Background: A link between progressive dental malocclusion, the use of a continuous positive airway pressure mask and GH-secreting pituitary macroadenoma (acromegaly) has not been previously reported. The present clinicopathological analysis stresses that tooth malposition should not be seen exclusively as a local process.

    Case Presentation: A 62-year-old caucasian man with no relevant medical history reported difficulty chewing food and perceived voice alteration during his annual periodontal check-up. Read More

    Octreotide-Associated Neutropenia.
    Pharmacotherapy 2017 May 10. Epub 2017 May 10.
    Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Department of Pharmacy Practice, Long Island University, Brooklyn, NY.
    Drug-induced neutropenia and agranulocytosis are rare adverse events but can be fatal. Neutropenia can be induced by a myriad of drugs from almost every pharmacologic class. Octreotide is a somatostatin analogue that has been used to treat variceal bleeding, acromegaly, and severe diarrhea associated with metastatic tumors, and to reduce symptoms in the setting of malignant bowel obstruction and pseudo-obstruction. Read More

    Granulomatous hypophysitis caused by Rathke's cleft cyst mimicking a growth hormone-secreting pituitary adenoma.
    Asian J Neurosurg 2017 Apr-Jun;12(2):283-286
    Department of Neurosurgery, Kyoto University Graduate School of Medicine, Kyoto 606-8507, Japan.
    We report a case of granulomatous hypophysitis caused by Rathke's cleft cyst (RCC) mimicking a growth hormone (GH)-secreting pituitary adenoma. Neuroradiological and endocrinological evaluations showed abnormal findings consistent with acromegaly: Magnetic resonance imaging demonstrated a pituitary mass lesion, and GH and insulin-like growth factor I levels were markedly elevated, and GH levels were not suppressed in oral glucose tolerance test. Transsphenoidal surgery was performed, but no adenomatous tissue could be detected. Read More

    How to investigate a child with excessive growth?
    Ann Endocrinol (Paris) 2017 May 5. Epub 2017 May 5.
    Paediatric Endocrinology Service, CHU d'Angers, 4, rue Larrey, 49000 Angers, France.
    The diagnostic approach to tall stature in children is based on collecting birth data (macrosomia), sizes and family puberty, a family history of constitutional or pathological tall stature, search for a delay of development, dysmorphia, disproportion, analysis of the growth velocity (normal or accelerated), general examination and assessment of puberty, and bone age. When there is a history of psychomotor retardation, a family history of pathological tall stature, or a disproportion in the clinical examination, the genetic causes of tall stature will be mentioned. The most frequent causes are Marfan syndrome and similar, Sotos syndrome, Beckwith-Wiedemann syndrome, Klinefelter syndrome, and MEN2B. Read More

    AIP mutations and gigantism.
    Ann Endocrinol (Paris) 2017 May 5. Epub 2017 May 5.
    Department of Endocrinology, Centre Hospitalier Universitaire de Liège, University of Liège, Domaine Universitaire du Sart-Tilman, 4000 Liège, Belgium. Electronic address:
    AIP mutations are rare in sporadic acromegaly but they are seen at a higher frequency among certain specific populations of pituitary adenoma patients (pituitary gigantism cases, familial isolated pituitary adenoma (FIPA) kindreds, and patients with macroadenomas who are diagnosed ≤30 years). AIP mutations are most prevalent in patients with pituitary gigantism (29% of this group were found to have mutations in AIP gene). These data support targeted genetic screening for AIP mutations/deletions in these groups of pituitary adenoma patients. Read More

    Growth hormone deficiency in treated acromegaly and active Cushing's syndrome.
    Best Pract Res Clin Endocrinol Metab 2017 Feb 9;31(1):79-90. Epub 2017 Mar 9.
    Endocrinology, Univeristy of Brescia, Italy. Electronic address:
    Growth hormone deficiency (GHD) in adults is characterized by reduced quality of life and physical fitness, skeletal fragility, increased weight and cardiovascular risk. It may be found in (over-) treated acromegaly as well as in active Cushing's syndrome. Hypopituitarism may develop in patients after definitive treatment of acromegaly, although the exact prevalence of GHD in this population is still uncertain because of limited awareness, and scarce and conflicting data so far available. Read More

    Controversies in the risk of neoplasia in GH deficiency.
    Best Pract Res Clin Endocrinol Metab 2017 Feb 22;31(1):35-47. Epub 2017 Feb 22.
    University of Belgrade, School of Medicine, Dr Subotica 8, 11000 Belgrade, Serbia. Electronic address:
    Growth hormone (GH) replacement in GH deficient (GHD) children secures normal linear growth, while in GHD adults it improves metabolic status, body composition and quality of life. Safety of GH treatment is an important issue in particular concerning the controversy of potential cancer risk. Unlike in congenital IGF-1 deficiency, there is no complete protection against cancer in GHD patients. Read More

    3D Volumetric Measurements of GH Secreting Adenomas Correlate with Baseline Pituitary Function, Initial Surgery Success Rate, and Disease Control.
    Horm Metab Res 2017 May 4. Epub 2017 May 4.
    Section on Endocrinology and Genetics, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA.
    There is scarce data on the clinical utility of volume measurement for growth hormone (GH)-secreting pituitary adenomas. The current study objective was to assess the association between pituitary adenoma volumes and baseline endocrine evaluation, initial surgical success rate, and disease control among patients with acromegaly. A retrospective cohort study was conducted at a clinical research center including patients with acromegaly due to GH-secreting pituitary adenomas. Read More

    An intrasellar pituitary adenoma-gangliocytoma presenting as acromegaly.
    Endocrinol Diabetes Metab Case Rep 2017 27;2017. Epub 2017 Apr 27.
    Departments of Endocrinology and Diabetes.
    Most cases of acromegaly are due to growth hormone (GH)-secreting pituitary adenomas arising from somatotroph cells. Mixed pituitary adenoma and gangliocytoma tumours are rare and typically associated with hormonal hypersecretion, most commonly GH excess. Differentiating these mixed tumours from conventional pituitary adenomas can be difficult pre-operatively, and careful histological analysis after surgical resection is key to differentiating the two entities. Read More

    Primary hypertrophic osteoarthropathy due to a novel SLCO2A1 mutation masquerading as acromegaly.
    Endocrinol Diabetes Metab Case Rep 2017 19;2017. Epub 2017 Apr 19.
    Department of Endocrinology, Centre Hospitalier Universitaire de Liège, University of Liège, LiègeBelgium.
    Summary: A 20-year-old man with an 8-year history of progressive enlargement of his hands and feet, coarsening facial features, painful joints and thickened, oily skin was referred for investigation of acromegaly. On examination, the subject was of normal height and weight. He had markedly increased skin thickness around the forehead, eyelids and scalp with redundant skin folds. Read More

    A unique acromegalic osteoarthropathy: manubriosternal joint arthritis.
    Clin Case Rep 2017 May 29;5(5):725-726. Epub 2017 Mar 29.
    Endocrine Center of Okayama University HospitalOkayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences2-5-1 Shikata-cho, KitakuOkayama700-8558Japan.
    Osteoarthritis of the manubriosternal joint can be found in patients with inflammatory arthritis. Acromegalic arthropathy is often found in the shoulders, wrists, knees, hips, and spine; however, attention should also be given to sternalgia as a complication of acromegalic involvement of the manubriosternal joint. Read More

    Outcome of Endoscopic Transsphenoidal Surgery for Acromegaly.
    World Neurosurg 2017 Apr 29. Epub 2017 Apr 29.
    Pituitary Center; Department of Neurosurgery, Seoul National University College of Medicine. Electronic address:
    Objective: Endoscopic transsphenoidal surgery has recently been introduced in pituitary surgery. We investigated outcomes and complications of endoscopic surgery in two referral centers in Korea.

    Methods: We enrolled 134 patients with acromegaly (microadenomas, n=15; macroadenomas, n=119) who underwent endoscopic transsphenoidal surgery at Seoul National University Hospital (n=74) and Samsung Medical center (n=60) between Jan 2009 and Mar 2016. Read More

    Acromegalic Cardiomyopathy With Malignant Arrhythmogenic Pattern Successfully Treated With Mechanical Circulatory Support and Heart Transplantation.
    Can J Cardiol 2017 Feb 21. Epub 2017 Feb 21.
    Department of Cardiothoracic Science, University Hospital S. Maria della Misericordia, and IRCAB Foundation, Udine, Italy.
    Cardiovascular involvement is common in acromegaly and can lead to development of acromegalic cardiomyopathy, characterized by concentric biventricular hypertrophy with a progressive impairment of diastolic and systolic function. The onset of heart failure and arrhythmias are related to poor prognosis. We report on a case of a 48-year-old man with acromegalic cardiomyopathy caused by pituitary adenoma. Read More

    Clinical Importance of Somatostatin Receptor 2 (SSTR2) and Somatostatin Receptor 5 (SSTR5) Expression in Thyrotropin-Producing Pituitary Adenoma (TSHoma).
    Med Sci Monit 2017 Apr 23;23:1947-1955. Epub 2017 Apr 23.
    Department of Clinical Laboratory, People's Hospital of Weifang, Weifang, Shandong, China (mainland).
    BACKGROUND Thyrotropin-secreting pituitary adenomas (TSHomas) are a rare cause of hyperthyroidism. Somatostatin analogs have proved to be effective for inhibiting pituitary hormones secretion, working via interactions with somatostatin receptors (SSTRs). Moreover, antiproliferative activity of somatostatin analog is now demonstrated in several studies. Read More

    Assessment of lung function in a large cohort of patients with acromegaly.
    Eur J Endocrinol 2017 Jul 21;177(1):15-23. Epub 2017 Apr 21.
    Medizinische Klinik und Poliklinik IVKlinikum der Universität München und Lungentumorzentrum München, Germany.
    Objective: Acromegaly is associated with increased mortality due to respiratory disease. To date, lung function in patients with acromegaly has only been assessed in small studies, with contradicting results. We assessed lung function parameters in a large cohort of patients with acromegaly. Read More

    Role of Phosphodiesterases on the Function of Aryl Hydrocarbon Receptor-Interacting Protein (AIP) in the Pituitary Gland and on the Evaluation of AIP Gene Variants.
    Horm Metab Res 2017 Apr 20;49(4):286-295. Epub 2017 Apr 20.
    Section on Endocrinology and Genetics (SEGEN), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), Bethesda, MD, USA.
    Familial isolated pituitary adenoma (FIPA) is caused in about 20% of cases by loss-of-function germline mutations in the AIP gene. Patients harboring AIP mutations usually present with somatotropinomas resulting either in gigantism or young-onset acromegaly. AIP encodes for a co-chaperone protein endowed with tumor suppressor properties in somatotroph cells. Read More

    Suffocation due to Thoracic Deformity Caused by Acromegaly.
    Intern Med 2017 15;56(8):949-951. Epub 2017 Apr 15.
    Department of Acute Critical Care Medicine, Shizuoka Hospital, Juntendo University, Japan.
    A 61-year-old man with gigantism and acromegaly choked and fell into a coma. Immediate tracheal intubation resulted in a return of his consciousness. Enhanced computed tomography indicated that the trachea and left main bronchus were compressed by the thoracic spine and sternum. Read More

    HIGH-DOSE AND HIGH-FREQUENCY LANREOTIDE AUTOGEL IN ACROMEGALY: A RANDOMIZED, MULTICENTER STUDY.
    J Clin Endocrinol Metab 2017 Apr 17. Epub 2017 Apr 17.
    Division of Endocrinology and Metabolism, University of Turin, Italy.
    Context: The increase in drug frequency or dose is recommended for acromegaly patients with partial response to long-acting somatostatin receptor ligands (SRLs). However, the efficacy and safety data with lanreotide autogel (LAN-ATG) at high-dose (HD) or high-frequency (HF) are still scanty and anecdotal.

    Objective: To evaluate the biochemical efficacy and safety of HF- and HD LAN-ATG in patients with active acromegaly. Read More

    Endocrine Comorbidities in Patients with Psoriatic Arthritis: A Population-based Case-controlled Study.
    J Rheumatol 2017 Apr 15. Epub 2017 Apr 15.
    From the Department of Rheumatology, and the Department of Internal Medicine, and the Department of Community Medicine and Epidemiology, Carmel Medical Center; Bruce and Ruth Rappaport Faculty of Medicine Technion, Haifa; Chief Physician's Office, Central Headquarters, Clalit Health Services, Tel Aviv; Siaal Research Center for Family Medicine and Primary Care, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheba, Israel. A. Haddad, MD, Department of Rheumatology, Carmel Medical Center; R.I. Ashkenazi, MD, Department of Internal Medicine, Carmel Medical Center; H. Bitterman, MD, Chief Physician's Office, Central Headquarters, Clalit Health Services, and Bruce and Ruth Rappaport Faculty of Medicine Technion; I. Feldhamer, MA, Chief Physician's Office, Central Headquarters, Clalit Health Services; S. Greenberg-Dotan, PhD, Chief Physician's Office, Central Headquarters, Clalit Health Services; I. Lavi, MA, MPH, Department of Community Medicine and Epidemiology, Carmel Medical Center; E. Batat, MBA, Chief Physician's Office, Central Headquarters, Clalit Health Services; I. Bergman, MD, Professor, Department of Internal Medicine, Carmel Medical Center; A.D. Cohen, PhD, MD, MPH, Chief Physician's Office, Central Headquarters, Clalit Health Services, and Siaal Research Center for Family Medicine and Primary Care, Faculty of Health Sciences, Ben-Gurion University of the Negev; D. Zisman, MD, Department of Rheumatology, and Department of Community Medicine and Epidemiology, Carmel Medical Center. Dr. Haddad and Dr. Ashkenazi contributed equally to this work. Dr. Cohen and Dr. Zisman contributed equally to this work. Address correspondence to Dr. D. Zisman, Department of Rheumatology, Carmel Medical Center, 7 Michal St., Haifa 34362, Israel. E-mail: Accepted for publication February 21, 2017.
    Objective: To investigate endocrine comorbidities in patients with psoriatic arthritis (PsA).

    Methods: A retrospective, cross-sectional study was performed with the database of Clalit Health Services, the largest healthcare provider in Israel, between 2002 and 2014. Patients with PsA were identified and matched by age and sex to healthy controls. Read More

    Calcium and bone turnover markers in acromegaly: a prospective controlled study.
    J Clin Endocrinol Metab 2017 Apr 12. Epub 2017 Apr 12.
    Emory University School of Medicine, 1648 Pierce Drive Northeast, Atlanta GA 30307.
    Context: Acromegaly has been associated with calcium-phosphate and bone turnover alterations. Controlled studies of these interactions are sparse.

    Objective: To evaluate calcium and bone metabolism in active and treated acromegaly. Read More

    The acylated/unacylated ghrelin ratio is similar in acromegaly patients during different treatment regimens.
    J Clin Endocrinol Metab 2017 Apr 11. Epub 2017 Apr 11.
    Department of Internal Medicine, Section Endocrinology, Erasmus MC, Rotterdam, the Netherlands.
    Background: Data on plasma acylated ghrelin (AG) and unacylated ghrelin (UAG) levels in acromegaly are limited. High ratios of AG/UAG are linked with type 2 diabetes, obesity and hyperphagia (e.g. Read More

    Expression of Somatostatin Receptor 2 in Somatotropinoma Correlated with the Short-Term Efficacy of Somatostatin Analogues.
    Int J Endocrinol 2017 15;2017:9606985. Epub 2017 Mar 15.
    Division of Endocrinology and Metabolism, Huashan Hospital, Fudan University, Shanghai 200040, China; Institute of Endocrinology and Diabetology, Fudan University, Shanghai 200040, China; Shanghai Pituitary Tumor Center, Shanghai 200040, China.
    The expression of somatostatin receptor subtypes (SSTRs) in pituitary growth hormone- (GH-) secreting adenomas may predict the response to somatostatin analogues (SSA). Our aim was to evaluate the value of the immunohistochemical (IHC) scores of 2 subtypes, SSTR2 and SSTR5, in predicting the short-term efficacy of SSA therapy in patients with active acromegaly. Ninety-three newly diagnosed acromegalic patients were included in our study. Read More

    N-myc downstream-regulated gene 2 (NDRG2) promoter methylation and expression in pituitary adenoma.
    Diagn Pathol 2017 Apr 8;12(1):33. Epub 2017 Apr 8.
    Neuroscience Institute, Lithuanian University of Health Sciences, Eiveniu str.4, LT-50009, Kaunas, Lithuania.
    Background: Pituitary adenoma (PA) is a benign primary tumor that arises from the pituitary gland and is associated with ophthalmological, neurological and endocrinological abnormalities. However, causes that increase tumor progressing recurrence and invasiveness are still undetermined. Several studies have shown N-myc downstream regulated gene 2 (NDRG2) as a tumor suppressor gene, but the role of NDRG2 gene in pituitary adenoma pathogenesis has not been elucidated. Read More

    Marked alteration of glycemic profile surrounding lanreotide administration in acromegaly: a case report.
    J Diabetes Investig 2017 Apr 8. Epub 2017 Apr 8.
    Division of Nephrology, Hypertension and Endocrinology, Department of Internal Medicine, Nihon University School of Medicine.
    Whether somatostatin analogs for acromegaly improve or worsen a patient's glycemic profile is controversial. A risk of hypoglycemia should be presumed especially when patients receive insulin therapy, as the package inserts caution. However, a detailed clinical course of such a case was never reported in research articles. Read More

    Current best practice in the management of patients after pituitary surgery.
    Ther Adv Endocrinol Metab 2017 Mar 1;8(3):33-48. Epub 2017 Mar 1.
    Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, Johns Hopkins University, 1830 East Monument Street #333, Baltimore, MD 21287, USA.
    Sellar and parasellar masses are a common finding, and most of them are treated surgically via transsphenoidal approach. This type of surgery has revolutionized the approach to several hypothalamic-pituitary diseases and is usually effective, and well-tolerated by the patient. However, given the complex anatomy and high density of glandular, neurological and vascular structures in a confined space, transsphenoidal surgery harbors a substantial risk of complications. Read More

    Vitamin D across growth hormone (GH) disorders: From GH deficiency to GH excess.
    Growth Horm IGF Res 2017 Apr 27;33:35-42. Epub 2017 Feb 27.
    Section of Endocrinology, Biomedical Department of Internal and Specialist Medicine (DIBIMIS), University of Palermo, Piazza delle Cliniche 2, 90127 Palermo, Italy. Electronic address:
    The interplay between vitamin D and the growth hormone (GH)/insulin-like growth factor (IGF)-I system is very complex and to date it is not fully understood. GH directly regulates renal 1 alpha-hydroxylase activity, although the action of GH in modulating vitamin D metabolism may also be IGF-I mediated. On the other hand, vitamin D increases circulating IGF-I and the vitamin D deficiency should be normalized before measurement of IGF-I concentrations to obtain reliable and unbiased IGF-I values. Read More

    Treatment adherence and persistence with long-acting somatostatin analog therapy for the treatment of acromegaly: a retrospective analysis.
    BMC Pharmacol Toxicol 2017 Apr 4;18(1):22. Epub 2017 Apr 4.
    Ipsen Biopharmaceuticals, Inc, 106 Allen Road, Basking Ridge, NJ, 07920, USA.
    Background: Many patients with acromegaly require medical treatment that includes somatostatin analogs (SSAs). Long-acting SSA formulations are widely used, due in part to increased patient convenience and increased treatment adherence vs daily medications. Although medication compliance can be poor in patients with chronic conditions, adherence and persistence with these SSAs in patients with acromegaly has not been evaluated. Read More

    Long-Term Endocrine Outcomes Following Endoscopic Endonasal Transsphenoidal Surgery for Acromegaly and Associated Prognostic Factors.
    Neurosurgery 2017 Mar 29. Epub 2017 Mar 29.
    Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, California.
    Background: Long-term remission rates from endoscopic transsphenoidal surgery for acromegaly and their relationship to prognostic indicators of disease aggressiveness are not well documented.

    Objective: To investigate long-term remission rates in patients with acromegaly after endoscopic transsphenoidal surgery, and correlate this with molecular and radiographic markers of disease aggressiveness.

    Methods: We identified all patients undergoing endoscopic transsphenoidal surgery for acromegaly from 2005 to 2013 at Cedars-Sinai Pituitary Center. Read More

    Utility of baseline serum phosphorus levels for predicting remission in acromegaly patients.
    J Endocrinol Invest 2017 Mar 29. Epub 2017 Mar 29.
    Division of Endocrinology and Metabolism Disorders, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Capa, 34090, Istanbul, Turkey.
    Purpose: High GH and IGF I levels increase tubular phosphate reabsorption in patients with acromegaly. We aimed to investigate the utility of serum phosphorus levels as an indicator for predicting chance of remission in acromegaly patients.

    Design: Fifty-one patients (n: 51; F: 24, M: 27) with diagnosis of acromegaly were included in the study. Read More

    MANAGEMENT OF ENDOCRINE DISEASE: Quality of life tools for the management of pituitary disease.
    Eur J Endocrinol 2017 Jul 28;177(1):R13-R26. Epub 2017 Mar 28.
    Hospital Sant PauIIB-Sant Pau, Research Center for Pituitary Diseases, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER, Unidad 747), ISCIII, and Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
    Background: In the last few years, quality of life (QoL) has become an outcome measure in patients with pituitary diseases.

    Objective: To describe the available data on QoL impairment evaluated with questionnaires in patients with pituitary diseases.

    Design: Critical review of the pertinent literature and pragmatic discussion of available information. Read More

    Acromegalic arthropathy in various stages of the disease: an MRI study.
    Eur J Endocrinol 2017 Jun 27;176(6):779-790. Epub 2017 Mar 27.
    Departments of Endocrinology & Metabolic Diseases and Center for Endocrine Tumors Leiden.
    Background: Arthropathy is a prevalent and invalidating complication of acromegaly with a characteristic radiographic phenotype. We aimed to further characterize cartilage and bone abnormalities associated with acromegalic arthropathy using magnetic resonance imaging (MRI).

    Methods: Twenty-six patients (23% women, mean age 56. Read More

    Paraneoplastic endocrine syndromes.
    Endocr Relat Cancer 2017 Jun 24;24(6):R173-R190. Epub 2017 Mar 24.
    Oxford Centre for DiabetesEndocrinology and Metabolism, University of Oxford, Oxford, UK.
    The majority of neoplasms are responsible for symptoms caused by mass effects to surrounding tissues and/or through the development of metastases. However, occasionally neoplasms, with or without endocrine differentiation, acquire the ability to secrete a variety of bioactive substances or induce immune cross-reactivity with the normal tissues that can lead to the development of characteristic clinical syndromes. These syndromes are named endocrine paraneoplastic syndromes when the specific secretory components (hormones, peptides or cytokines) are unrelated to the anticipated tissue or organ of origin. Read More

    Body mass index and insulin-like growth factor 1 as risk factors for discordant growth hormone and insulin-like growth factor 1 levels following pituitary surgery in acromegaly.
    J Formos Med Assoc 2017 Mar 21. Epub 2017 Mar 21.
    Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; China Pituitary Disease Registry Center, Chinese Pituitary Adenoma Cooperative Group, Beijing, China. Electronic address:
    Background: Growth hormone (GH)-secreting pituitary adenoma is a chronic disease characterized by excess levels of GH and insulin-like growth factor 1 (IGF-1). Based on our clinical experience and observations, we identified discordant GH and IGF-1 levels after surgery. The risk factors for this phenomenon are unclear, and individualized cure, control criteria, and management after surgery should be considered. Read More

    Matrix metalloproteinase 2 (MMP-2) levels are increased in active acromegaly patients.
    Endocrine 2017 Mar 22. Epub 2017 Mar 22.
    Department of Endocrinology and Metabolism, Kocaeli University Faculty of Medicine, Kocaeli, Turkey.
    Purpose: During follow-up of acromegaly patients, there is a discordance rate of 30% between the measurements of growth hormone and insulin-like growth factor-1 levels. Further tests are required to determine disease activity in patients with discordant results. This study was planned to investigate an association of serum levels of matrix metalloproteinase-2, matrix metalloproteinase-9, and cathepsin B with disease activity in acromegaly patients. Read More

    Persistent reduction of circulating myeloid calcifying cells in acromegaly. Relevance to the bone-vascular axis.
    J Clin Endocrinol Metab 2017 Mar 17. Epub 2017 Mar 17.
    Department of Medicine, University of Padova, 35128 Padova, Italy.
    Context: Acromegaly is a systemic disease characterized by persistent bone pathology and excess cardiovascular mortality. Despite multiple concomitant risk factors, atherosclerosis does not seem to be accelerated in acromegaly.

    Objective: To compare the levels of circulating myeloid calcifying cells (MCCs), which promote ectopic calcification and inhibit angiogenesis, in individuals with or without acromegaly. Read More

    Rapid Onset of Diabetic Ketoacidosis After SGLT2 Inhibition in a Patient With Unrecognized Acromegaly.
    J Clin Endocrinol Metab 2017 May;102(5):1451-1453
    Division of Endocrinology and Diabetes, Kantonsspital St. Gallen, 9007 St. Gallen, Switzerland.
    Context: Diabetic ketoacidosis has been described as a rare complication of acromegaly and may be observed in 1% of affected patients. The well-described direct lipolytic effect of growth hormone results in increased availability of free fatty acids (FFAs) for hepatic ketogenesis and is an important pathogenic event. More recently, ketoacidosis has been identified as an important complication of sodium-glucose-transport-protein 2 inhibitors (SGLT2i). Read More

    In vitro head-to-head comparison between octreotide and pasireotide in GH-secreting pituitary adenomas.
    J Clin Endocrinol Metab 2017 Mar 13. Epub 2017 Mar 13.
    Department of Internal Medicine, Division Endocrinology and.
    Context: First-generation somatostatin analogs (SSAs), such as octreotide (OCT), are the first line medical therapy for acromegaly. Pasireotide (PAS), a newly developed SSA, has shown promising results in the treatment of acromegaly.

    Objective: To compare the anti-secretory effect of OCT and PAS in primary cultures of GH-secreting pituitary adenomas (GH-omas). Read More

    1 OF 194